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INTRODUCTION
Twentieth century medical practice placed
an emphasis on history and examination
skills, as expounded by William Osler. A
clinical impression would be formed and
laboratory tests would then conﬁrm,
reﬁne or refute the diagnosis. This para-
digm incorporates the concept of pretest
probability — a Bayesian approach
whereby the post-test probability of a
disease is inﬂuenced by the sensitivity and
speciﬁcity of the test and the pretest prob-
ability (ie, likelihood) of the disease.
In modern practice this order is often
reversed; test results may be available
before the patient is seen. The manner in
which results are presented (based on the
software used), for example, ‘abnormal’
results in red and ‘normal’ results in
black, can lead to an undue binary distinc-
tion in the mind of the clinician.
Compounding this, often a patient-
centred reference range cannot be pro-
vided by the laboratory as relevant clinical
information is missing. This may lead to
misinterpretation of the result (postanaly-
tical error). Inconclusive or abnormal
results may lead to a cascade of further
investigations to conﬁrm or refute the
initial tests.
The historic paradigm of estimating
pretest probability, followed by laboratory
tests to reﬁne the likelihood of disease,
frequently no longer applies. New
approaches are needed to remind clini-
cians that if results are available before a
consultation, they must not be taken in
isolation but should be considered in rela-
tion to the clinical impression. One
approach may be to provide a quantitative
indication of the quality of a blood test
result—the measurement uncertainty
(MU). The MU is the value associated
with the result of a measurement that
characterises the dispersion of the values
that could reasonably (eg, with a given
probability/conﬁdence level) be attributed
to the measurement.
Could routine provision of MU with a
blood result reduce postanalytical error?
Only time will tell with MU being made
available for routine clinical use.
What is MU?
A repeated measurement on the same sample
generally produces different values—even if
measuring conditions are constant. Thus
repeated measurements do not produce a
single value—there is uncertainty as to the
true value of the measured quantity.
Biological variation (natural ﬂuctuation of
body ﬂuid constituents around a homoeo-
static set point) also exists. For example, the
biological variation of creatinine in healthy
subjects is 4–5%.
A single blood sample could be mea-
sured for a range of indices. The term
‘measurand’ signiﬁes ‘the quantity
intended to be measured’. The ‘Guide to
the Expression of Uncertainty in
Measurement’ from the International
Organization for Standardization states
that “in general, the result of a measure-
ment is only an approximation or estimate
of the value of the measurand and thus is
complete only when accompanied by a
statement of the uncertainty of that esti-
mate”. In other words, without an indica-
tion of the result quality, measurement
results cannot be meaningfully compared
with a reference value. This could be
problematic if the measurement result is
relied upon to distinguish disease from no
disease, such as a D-dimer >500 ng/mL
to change the probability of a pulmonary
embolus.
MU does not imply doubt about the
validity of a measurement; on the con-
trary, it implies increased conﬁdence of
the result’s validity. A result outside the
range of uncertainty must, by deﬁnition,
be considered certain. For example, at a
reported creatinine concentration of
150 μmol/L (using the widely available
Jaffe method) the SD is approximately
4 μmol/L. Although we cannot be sure the
creatinine concentration is precisely
150 mmol/L we can say, with 95% conﬁ-
dence that it is within 2 SD of this, that
is, in the range 142–158 μmol/L. Hence,
uncertainty assessment is required to
decide if the result is adequate for its
intended purpose and to ascertain if it is
consistent with other similar or previous
results. In this example, underappreciation
of MU may lead to misclassiﬁcation of
estimated glomerular ﬁltration rate
(eGFR).
What causes MU?
MU is an inescapable part of laboratory
practice and is not ‘error’. Error is the dif-
ference between the measured value and
the ‘true’ value whereas uncertainty is a
quantiﬁcation of doubt about the meas-
urement result. Uncertainty is caused by
the interplay of errors which create dis-
persion around the estimated value of the
measurand; the smaller the dispersion, the
smaller the uncertainty.
Sources for MU
The premeasurement phase includes spe-
cimen collection technique, sample trans-
port, storage temperature/time or
within-individual biological variation. The
measurement phase is inﬂuenced by
laboratory temperature, humidity and dust
that may affect the sample stability, meas-
uring systems (eg, balances), thermometer
calibrations, reagents—including batch
variation and calibrators. There is an
ongoing debate as to how uncertainty
should be determined and expressed for
measurements of biological substances,
with many theoretical and practical issues
still needing to be resolved.
Expression of MU
The SD or coefﬁcients of variation (CVs)
of results achieved for the appropriate
internal quality control are the most
recognised. The CV may vary according
to the concentration of the analyte, for
example, troponin has increasing CVs as
the concentration approaches zero—
indeed, the concentration at which the
CV is 10% has determined the lower limit
of troponin reporting. Clinicians may not
be aware that CVs can vary within and
between assays—ranging from <1% to
>20% depending on the analyte mea-
sured, its concentration and the analytical
method used.
The 95% CI is calculated from the SD
and gives a range over which the measur-
and is considered to sit. The interval may
span a threshold with the reported value
sitting above (or below) the diagnostic
threshold. In this situation the clinician
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must draw upon their clinical impression,
based upon history and examination, to
interpret the result. A problem with this
approach is it would require a step-change
in clinician behaviour as in ordinary usage
the term ‘uncertainty’ doesn’t inspire con-
ﬁdence. However, if the laboratory use of
the term is understood then clinicians
may feel liberated and more in control of
the clinical case. On the other hand, if a
result spans a diagnostic threshold, a clin-
ician might overinvestigate as they would
be fearful of missing important diagnoses.
Repeating the test may reduce the chance
of overinvestigation with invasive or
expensive tests. However, the effect of
reporting MU with results requiring
urgent clinical assessment and treatment
such as potassium >6.5 mmol/L or
glucose <2.0 mmol/L will need to be
considered.
Reporting of MU will not eliminate
postanalytical (clinician) error but it may
prove to be one small step to restoring the
importance of clinical observation
reported by Osler over 100 years ago.
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